Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The complex pathophysiology of allergic rhinitis : Scientific rationale for the development of an alternative treatment option

Bjermer, Leif LU ; Westman, Marit ; Holmström, Mats and Wickman, Magnus C. (2019) In Allergy, Asthma and Clinical Immunology 15(1).
Abstract


Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained... (More)


Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista
®
, Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Allergic rhinitis, Azelastine, Fluticasone, MP-AzeFlu
in
Allergy, Asthma and Clinical Immunology
volume
15
issue
1
article number
24
publisher
BioMed Central (BMC)
external identifiers
  • scopus:85064462317
  • pmid:31015846
ISSN
1710-1492
DOI
10.1186/s13223-018-0314-1
language
English
LU publication?
yes
id
4c7c268a-c04e-42df-9c4a-e5e9e887ec7a
date added to LUP
2019-05-03 10:53:54
date last changed
2024-07-09 11:07:23
@article{4c7c268a-c04e-42df-9c4a-e5e9e887ec7a,
  abstract     = {{<p><br>
                                                         Allergic rhinitis (AR) poses a global health problem and can be challenging to treat. Many of the current symptomatic treatments for AR have been available for decades, yet there has been little improvement in patient quality of life or symptom burden over the years. In this review, we ask why this might be and explore the pathophysiological gaps that exist within the various AR treatment classes. We focus on the benefits and drawbacks of different treatment options and delivery routes for AR treatments and consider how, given what is known about AR pathophysiology and symptomatology, patients may be offered more effective treatment options for rapid, effective, and sustained AR control. In particular, we consider how a new AR preparation, MP-AzeFlu (Dymista                             <br>
                            <sup>®</sup><br>
                                                         , Meda, Sweden), comprising a formulation of an intranasal antihistamine (azelastine hydrochloride), an intranasal corticosteroid (fluticasone propionate), and excipients delivered in a single spray, may offer benefits over and above single and multiple AR therapy options. We review the evidence in support of this treatment across the spectrum of AR disease. The concept of AR control is also reviewed within the context of new European Union and Contre les Maladies Chroniques pour un VIeillissement Actif-Allergic Rhinitis and its Impact on Asthma initiatives.                         <br>
                        </p>}},
  author       = {{Bjermer, Leif and Westman, Marit and Holmström, Mats and Wickman, Magnus C.}},
  issn         = {{1710-1492}},
  keywords     = {{Allergic rhinitis; Azelastine; Fluticasone; MP-AzeFlu}},
  language     = {{eng}},
  month        = {{04}},
  number       = {{1}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{Allergy, Asthma and Clinical Immunology}},
  title        = {{The complex pathophysiology of allergic rhinitis : Scientific rationale for the development of an alternative treatment option}},
  url          = {{http://dx.doi.org/10.1186/s13223-018-0314-1}},
  doi          = {{10.1186/s13223-018-0314-1}},
  volume       = {{15}},
  year         = {{2019}},
}